Wisconsin Biotech Firm Secures $1.8M NIH Grant to Advance Diabetes Cure

Regenerative Medical Solutions (RMS), a biotechnology company based in Madison, Wisconsin, has been awarded a significant grant from the National Institutes of Health (NIH) to further its research into a potential cure for diabetes.

The peer-reviewed Phase II Small Business Innovation Research (SBIR) grant, valued at approximately $1.8 million, will enable the company to move its innovative treatment to the next stage of clinical trials [1].

Founded on over 25 years of research, Regenerative Medical Solutions is a privately held company specializing in regenerative medicine and stem cell therapies.

The company is focused on developing a lasting cure for both type 1 and type 2 diabetes. Anthony Kolton, the CEO of RMS, expressed optimism following the announcement, stating, “This grant brings real hope for anyone suffering from diabetes; we’re one step closer to a functional cure, which would be life-changing for anyone affected by the disease” [1].

The core of RMS’s pioneering approach involves transforming human induced pluripotent stem cells (iPSCs) into insulin-producing cells (ILCs). These cells can then be transplanted into patients to restore the body’s natural ability to produce insulin and regulate blood glucose levels.

A key advantage of this method is its potential to eliminate the need for the heavy immunosuppressive drugs required by current transplant treatments—therapies that can lead to severe side effects, including death [1].

The company is currently in its proof-of-concept phase and will use the grant to fund a “humanized” animal study, which builds upon numerous successful preliminary tests conducted in petri dishes.

The goal is to create a safe and unlimited supply of insulin-producing cells that can be used as an effective therapy for a wide range of diabetic patients without the need for anti-rejection medications.

In conjunction with this scientific advancement, RMS is extending an invitation to investors to support its mission. The company highlights this as an opportunity to contribute to a socially impactful cause while also realizing a potential return on investment.

As an added incentive, the state of Wisconsin offers a 25% tax credit for in-state investors who back the company [1].

About Regenerative Medical Solutions

Regenerative Medical Solutions, Inc. (RMS) is a privately held biotechnology company focused on regenerative medicine and stem cell therapy for diabetes. Leveraging over 25 years of research, RMS is pioneering a potential cure for diabetes using human-induced pluripotent stem cell (iPSC) therapy. Our groundbreaking approach aims to offer a safe and effective solution for type 1 and type 2 diabetes and eliminates the need for anti-rejection drugs in diabetes treatment. RMS is committed to developing ethical, non-embryonic stem cell therapies to provide a lasting diabetes cure. This innovative biotech company operates in Madison, Wisconsin [1].